Organization (Academic)
Nanjing University
ClinicalTrials.gov lists Nanjing University as lead sponsor of 20 trials. It has 10 active development programs and 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo 中國之新民（THE NEW CITIZEN OF CHINA）, via Wikimedia Commons, CC BY-SA 3.0. Shown to identify the organization; it may be a registered trademark.
This page covers Nanjing University: 20 lead-sponsored trials and 1 legal-entity registration.
Disease areas (23)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Infertility | 9 |
| Infertility, Female | 5 |
| Lung Neoplasms | 2 |
| Parkinson Disease | 2 |
| Adenocarcinoma of Lung | 1 |
Showing 5 of 23 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 4 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 2 |
| 2015 | 2 |
| 2014 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (10)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| G-CSF | Infertility, Female | Phase 3 | 1 |
| G-CSF | Infertility | Phase 3 | 1 |
| Recombinant Luteinizing Hormone (rLH) | Infertility | Not reported | 1 |
| Gonadotropin-Releasing Hormone Agonist (GnRH-a) | Infertility | Not reported | 1 |
| Recombinant Follicle Stimulating Hormone | Infertility | Not reported | 1 |
Showing 5 of 10 active programs.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®) | 1 |
| Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®) | 1 |
| G-CSF | 1 |
| Progesterone | 1 |
| Ovitrelle | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 1 hit target (n=1) | 0 of 1 on time (n=1) |
Journals published in (43)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Fertility and sterility | 10 |
| Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology | 4 |
| Human reproduction (Oxford, England) | 4 |
| Frontiers in immunology | 2 |
| Reproductive biology and endocrinology : RB&E | 2 |
Showing 5 of 43 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 297 | 148 | 2025-12-30 |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Ministry of Ecology and Environment | Co sponsors trial with | 1 |
| Chinese Research Academy of Environmental Sciences | Co sponsors trial with | 1 |
| The Affiliated Jiangning Hospital of Nanjing Medical University | Co sponsors trial with | 1 |
| Jiangsu Province Nanjing Brain Hospital | Co sponsors trial with | 1 |
| Chinese Academy of Medical Sciences & Peking Union Medical College | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (326)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 326 events.
Biomarker capability evidence (16)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AMH | Trial sponsor | Named in trial inclusion criteria |
| AMH | Trial sponsor | Named in trial inclusion criteria |
| ERBB2 | Trial collaborator | Named in trial inclusion criteria |
| GNRH1 | Trial collaborator | Named in trial inclusion criteria |
| FOLH1 | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 16 evidence rows.
Biomarkers this organization publishes on (373)
Shown in this order: most publications first.
Showing 5 of 373 biomarkers.
On Scientist.com
Nanjing University is listed as a research supplier in the Scientist.com network.
Nanjing University provides academic research in a variety of scientific disciplines.
- Website
- www.nju.edu.cn
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Nanjing University on Scientist.com
For prices, more details, or to contact Nanjing University, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.